Mirion Technologies, Inc.

Mirion Technologies, Inc. is an American radiation detection and monitoring manufacturer headquartered in Atlanta, Georgia. Listed on the New York Stock Exchange under the ticker MIR, it reported revenue of USD 925.4 million in fiscal 2025 and employs 3,281 people.

Industry Position

Mirion measures a hazard the rest of this ranking does not touch. Where gas detectors quantify chemical concentration, Mirion instruments quantify ionising radiation: personal dose accumulated by an individual worker, ambient gamma levels in a controlled zone, alpha and beta contamination on surfaces, and neutron flux around reactor cores and spent fuel. These are measurements required by nuclear regulators rather than chosen by plant operators, which makes the product specification unusually rigid.

Fiscal 2025 was a turning point. Revenue rose 7.5% to USD 925.4 million and the company returned to profit with net income of USD 29.8 million, following losses of USD 36.6 million in 2024 and USD 98.7 million in 2023. The Nuclear & Safety segment produced USD 614.6 million, 66% of revenue, with Medical at USD 310.8 million.

Competitive Advantages

The barrier is materials rather than electronics. A gamma spectrometer's energy resolution is determined by the purity and crystalline structure of its high-purity germanium detector, and dosimetry depends on scintillation materials grown to exacting specifications. Mirion owns those processes and manufactures the sensing materials itself, which means it can set its own detection limits rather than inheriting a supplier's — the same vertical logic that separates Riken Keiki and Dräger from companies that assemble instruments around purchased sensors.

Demand is also structurally firming. The 10-K records order growth across all three nuclear verticals — new utility-scale reactors, the existing installed base, and small modular reactors — with roughly USD 150 million of large-opportunity orders in 2025. Defence radiation safety programmes add a second driver that does not follow commercial industrial cycles.

Challenges Ahead

Scale and history are the constraints. At USD 925.4 million of revenue Mirion is roughly half the size of MSA Safety, and it carried an accumulated deficit of USD 512.7 million at year end — a legacy of amortisation following its 2021 listing rather than of current trading. Annual net income only turned positive in 2025.

Growth is also substantially acquisition-led: the Nuclear & Safety segment's USD 53.5 million revenue increase is attributed in part to businesses bought during the year, which requires a continuing pipeline of suitable targets. The Medical segment grew 3.7% against the group's 7.5% and depends on hospital and radiotherapy capital budgets rather than on nuclear construction. Customer concentration in government-funded nuclear and defence programmes brings long procurement cycles and budget-cycle risk that no amount of manufacturing capability removes. VerityRank Score of 84/100.